Photo of Juan Pedraza

Juan Pedraza

Print ProfilePrint Profile


  • Psychiatry, American Board of Psychiatry and Neurology

  • Child & Adolescent Psychiatry


  • MD, Universidad El Bosque - Escuela Medicina Colombiana

  • Residency, Psychiatry
    Maimonides Medical Center/Conney Island Hosp

  • Fellowship, Child Psychiatry
    Mount Sinai Hospital


    Dr. Pedraza works at the ADHD center of excellence and makes part of the team conducting the following clinical trials:

    1. Imaging Stimulant and Non-stimulant Treatments for ADHD: A Network- based Approach

    This five year project examines similarities and differences in neural connectivity before and after treatment with methylphenidate and atomoxetine in youth with ADHD; and also examines the extent to which treatments produce improvement via normalization of function vs. adaptive change.  

    2. Improving identification of Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function in parents of children diagnosed with ADHD using objective measures

    This study will described the prevalence of ADHD and EF deficits in 50 biological mothers of inner-city youth undergoing treatment for ADHD using state-of-the-art clinical and objective assessment measures. It contributes new information regarding the role of the Quotient™ ADHD system as an adjunct tool for improving the sensitivity and specificity of ADHD diagnosis, and determine the extent to which Quotient™ indices are associated with EF deficits.

    3. Measuring and Predicting Response to Atomoxetine and Methylphenidate

    This two-site study evaluated the relative efficacy, tolerability and palatability of Concerta (methylphenidate) and ATX in the treatment of children and adolescents with ADHD, using a randomized, double blind, cross-over design.

    4. Methylphenidate and Atomoxetine in ADHD: fMRI Measures of Mechanisms and Response

    Functional magnetic resonance imaging (fMRI) was be used to better understand the neurobiological mechanisms of pharmacological treatments for ADHD.

    5. Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

    This study examines the mechanisms of action of Guanfacine extended release in the treatment of youth with ADHD using a pre/post fMRI design; scans are obtained while performing go/no-go and cued alerting tasks.

    6. A Phase 3, Double-blind Placebo-controlled, Multicentre Randomized –withdrawal, Long-term aintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Ages 6-17 with Attention-deficit/ Hyperactivity Disorder.

    This study evaluated the long-term maintenance of efficacy of SPD503 in children and adolescents (6-17) with attention-deficit/hyperactivity disorder (ADHD) who respond to an initial open-label, short-term treatment with SPD503. This was a double-blind, placebo controlled, randomized-withdrawal study design that involved a 7-week open-label dose optimization, followed by 6-week open-label maintenance of the optimized dose. Eligible subjects were randomized to either their assigned dose of SDP503 or matching placebo to evaluate the long-term maintenance of efficacy of the 26-week double-blind randomized withdrawal phase.

    7. A Combination of Scheduled Reduced Smoking (SGR) with Varenicline (VN) to Enhance Cessation. J. Erblich.

    This study aims to provide initial data on the efficacy of combined SGR+VN therapy with regard to smoking cessation, by assessing rates of abstinence and levels of smoking at 2 time points (4 and 12 weeks post quit) following a cessation attempt, in which smokers are randomized (n=48/group) to receive either SGR+VN, SGR+Placebo Drug, Basic Advice+VN, or Basic Advice+Placebo Drug, in a 2 x 2 factorial design.

    8. A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Reference Arm, in Adolescents Aged 13-17 with Attention-deficit/Hyperactivity Disorder (ADHD)

    9. A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH  with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)

    10.  Research project on Omega-3 fatty acids as an adjunctive therapy for stimulants in children diagnosed with ADHD. Pedraza JD. Collaborative grant with Glaxo Smith Kline – Maimonides Medical Center 2009.

    Financial & Billing Information

    Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.


  • 2012 -
    POND family foundation award


Pedraza J, Newcorn JH. Non-stimulant Treatment of ADHD. : Adler, Wilens, Spencer (Eds.) Attention-Deficit Hyperactivity Disorder in Adults and Children. Cambridge University Press ;.

Pedraza JD, Coffey B. Obsessive-compulsive disorder and comorbid attention-deficit/hyperactivity disorder: a complex diagnostic disentanglement and treatment. Journal of child and adolescent psychopharmacology 2013 Aug; 23(6).

Columbus AM, Pedraza J, Ivanov I, Otoy O, Newcorn J. Functional genetic variations and their role in aggressive behavior in the context of disruptive behavior disorders. Advances in Psychology Research 2012; 95.

Pedraza JD, Newcorn J. DSM-5 Clinical Cases. In: Conduct Disorder. Arlington, VA, American Psychiatric Publishing;.

Murillo M, Pedraza J. Psychosocial Aspects of Lung Cancer. Trastornos psicologicos y de la calidad de vida en pacientes con cancer de pulmon.. Psico-oncologia 2006; 3: 377-392.

Crawford RS, Albadawi H, Entabi F, Jones J, Atkins M, Pedraza J, LaMuraglia G, Watkins M. PJ34, A Potent Poly ADP-Ribose Inhibitor, Confers Local, But Not Systemic Protection In A Murine Model Of Bilateral Critical Limb Ischemia-Reperfusion . SVS Research Initiatives 2006;.

Crawford RS, Pedraza JD, Chung TK, Corey M, Conrad MF, Cambria RP. Functional outcome after thoracoabdominal aneurysm repair. Journal of vascular surgery 2008 Oct; 48(4).

Crawford RS, Chung TK, Hodgman T, Pedraza JD, Corey M, Cambria RP. Restenosis after eversion vs patch closure carotid endarterectomy. Journal of vascular surgery 2007 Jul; 46(1).

Conrad MF, Crawford RS, Pedraza JD, Brewster DC, Lamuraglia GM, Corey M, Abbara S, Cambria RP. Long-term durability of open abdominal aortic aneurysm repair. Journal of vascular surgery 2007 Oct; 46(4).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Pedraza did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


1160 Fifth Avenue Room 27
New York, NY 10029


1160 Fifth Avenue Room 31
New York, NY 10029

Tel: 212-241-9559

1160 5th Avenue
Basement, Office 24
New York, NY 10029

Tel: 212-241-9559
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash
  • Credit Card (Other)